Every 10-Q that Cross Country Healthcare Inc (CCRN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CCRN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CCRN filings page.
Cross Country Healthcare reported first-quarter 2026 results and highlighted a pending cash merger. Revenue from services was $241.1 million, down 17.8% from $293.4 million a year earlier, mainly from lower volumes in both operating segments. The company posted a net loss attributable to common stockholders of $4.3 million, or $0.14 per share, compared with a $0.5 million loss, or $0.02 per share, in the prior-year quarter.
Nurse and Allied Staffing generated $201.4 million of revenue, while Physician Staffing contributed $39.6 million, with segment contribution margins compressing in both areas. Cash and cash equivalents were $105.6 million and there were no borrowings under the $300 million asset-based credit facility, with $109.3 million of borrowing base availability. The company repurchased 657,653 shares for $5.8 million under its stock repurchase program. After quarter-end, Cross Country entered into a definitive Agreement and Plan of Merger under which its common shares will be converted into $13.25 in cash, and the company is expected to become a wholly owned subsidiary of KL Criss Cross Intermediate, LLC upon closing.
Cross Country Healthcare (CCRN) filed its Q3 2025 10‑Q, reporting revenue of $250,052 thousand and a net loss of $4,774 thousand, or $0.15 per diluted share. For the nine months, revenue was $817,532 thousand with a net loss of $11,923 thousand.
Results reflected softer volumes and several non-core charges. The quarter included $4,147 thousand of Aya Merger-related fees, $1,530 thousand of restructuring costs, and $1,102 thousand of legal and other losses. Operating loss was $5,973 thousand. Nurse and Allied Staffing generated $201,950 thousand of revenue; Physician Staffing contributed $48,102 thousand.
Liquidity remained solid: cash and cash equivalents were $99,132 thousand with no debt outstanding. The asset‑based revolver had $121.4 million of borrowing base availability, or $103.0 million net of $18.4 million in letters of credit. Operating cash flow was $30,012 thousand year‑to‑date. The pending Aya Merger remains subject to FTC review under the HSR Act; the HSR waiting period extends during the government shutdown, and the parties are discussing an end‑date extension.
Cross Country Healthcare (CCRN) Q2 2025 10-Q highlights:
- Revenue fell 19.3 % YoY to $274.1 million; six-month revenue declined 21.1 % to $567.5 million as travel-nurse volumes and bill rates continued to normalize.
- Loss from operations narrowed to $5.9 million (vs. $19.2 million loss LY). Net loss improved to $6.7 million or -$0.20 EPS (LY: -$0.47).
- Gross margin slipped 30 bp YoY to 20.4 % as lower pricing offset cost controls; SG&A down 17 % to $50.1 million.
- Operating cash flow was positive at $9.9 million YTD but sharply below $88.4 million LY, reflecting lower earnings and working-capital unwind.
- Balance sheet remains debt-free; cash & equivalents stable at $81.2 million. Equity totals $412.2 million (book value ≈ $12.7/share).
- Aya Healthcare take-private deal progressing: FTC issued a Second Request on 20 Feb 2025; close expected 4Q 2025. CCRN incurred $6.0 million Q2 and $8.0 million YTD in merger-related costs.
- Segments: Nurse & Allied supplied 82 % of revenue, down 23 %. Physician Staffing rose 3 % YoY.
- No share repurchases in Q2; $40.5 million remains authorized.
Key takeaways: While demand headwinds continue to pressure top line, CCRN preserved liquidity, maintained a debt-free balance sheet, and reduced losses. Future value for shareholders now hinges on successful completion of the Aya merger and potential go-private premium.